Is Antipsychotic Drug Use During Pregnancy Associated with Increased Malformation Rates and Worsening of Maternal and Infant Outcomes? A Systematic Review


Citar

Texto integral

Resumo

:There is much debate about continuing antipsychotic medication in patients who need it when they become pregnant because benefits must be weighed against potential teratogenic and malformation effects related to antipsychotics themselves. To address this, we conducted a systematic review on the PubMed, PsycINFO and CINHAL databases and the ClinicalTrials.gov register using the following strategy: (toxicity OR teratogenicity OR malformation* OR \"birth defect*\" OR \"congenital abnormality\" OR \"congenital abnormalities\" OR \"brain changes\" OR \"behavioral abnormalities\" OR \"behavioral abnormalities\") AND antipsychotic* AND (pregnancy OR pregnant OR lactation OR delivery OR prenatal OR perinatal OR post-natal OR puerperium) on September 27, 2023. We found 38 studies to be eligible. The oldest was published in 1976, while most articles were recent. Most studies concluded that the antipsychotics, especially the second-generation antipsychotics, were devoid of teratogenic potential, while few studies were inconclusive and recommended replication. Most authoritative articles were from the Boston area, where large databases were implemented to study the malformation potential of psychiatric drugs. Other reliable databases are from Northern European registers. Overall conclusions are that antipsychotics are no more related to malformations than the disorders themselves; most studies recommend that there are no reasons to discontinue antipsychotic medications in pregnancy

Sobre autores

Gabriele Sani

Department of Psychiatry,, Fondazione Policlinico Universitario Agostino Gemelli IRCCS,

Email: info@benthamscience.net

Tommaso Callovini

Department of Medicine and Surgery,, University of Milano-Bicocca

Email: info@benthamscience.net

Ottavia Ferrara

Department of Neuroscience, Section of Psychiatry, Università Cattolica del Sacro Cuore

Email: info@benthamscience.net

Daniele Segatori

Department of Neuroscience, Section of Psychiatry,, Università Cattolica del Sacro Cuore

Email: info@benthamscience.net

Stella Margoni

Department of Neuroscience, Section of Psychiatry,, Università Cattolica del Sacro Cuore

Email: info@benthamscience.net

Alessio Simonetti

Department of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Email: info@benthamscience.net

Francesco Lisci

Department of Neuroscience, Section of Psychiatry,, Università Cattolica del Sacro Cuore

Email: info@benthamscience.net

Giuseppe Marano

Department of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Email: info@benthamscience.net

Alessia Fischetti

Department of Neuroscience, Section of Psychiatry,, Università Cattolica del Sacro Cuore

Email: info@benthamscience.net

Georgios Kotzalidis

Department of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Autor responsável pela correspondência
Email: info@benthamscience.net

Federica Di Segni

Psychiatry Residency Training Programme, Faculty of Medicine and Psychology, Sapienza University of Rome

Email: info@benthamscience.net

Federica Fiaschè

ASL RM1, Presidio Ospedaliero San Filippo Neri, Servizio Psichiatrico di Diagnosi e Cura

Email: info@benthamscience.net

Delfina Janiri

Department of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Email: info@benthamscience.net

Lorenzo Moccia

Department of Psychiatry,, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Email: info@benthamscience.net

Giovanni Manfredi

UOC Psichiatria, Day Hospital, Sant'Andrea Teaching Hospital, Sapienza University of Rome

Email: info@benthamscience.net

Alessandro Alcibiade

Psychiatry Residency Training Programme, Faculty of Medicine and Psychology, Sapienza University of Rome

Email: info@benthamscience.net

Caterina Brisi

Department of Neuroscience, Section of Psychiatry,, Università Cattolica del Sacro Cuore

Email: info@benthamscience.net

Flavia Grisoni

Department of Neuroscience, Section of Psychiatry,, Università Cattolica del Sacro Cuore

Email: info@benthamscience.net

Gianmarco Stella

Department of Neuroscience, Section of Psychiatry, Università Cattolica del Sacro Cuore

Email: info@benthamscience.net

Evelina Bernardi

Department of Neuroscience, Section of Psychiatry, Università Cattolica del Sacro Cuore

Email: info@benthamscience.net

Andrea Brugnami

Department of Neuroscience, Section of Psychiatry, Università Cattolica del Sacro Cuore

Email: info@benthamscience.net

Michele Ciliberto

Department of Neuroscience, Section of Psychiatry,, Università Cattolica del Sacro Cuore

Email: info@benthamscience.net

Maria Spera

Department of Neuroscience, Section of Psychiatry, Università Cattolica del Sacro Cuore,

Email: info@benthamscience.net

Romina Caso

Department of Neuroscience, Section of Psychiatry, Università Cattolica del Sacro Cuore,

Email: info@benthamscience.net

Sara Rossi

Department of Neuroscience, Section of Psychiatry, Università Cattolica del Sacro Cuore

Email: info@benthamscience.net

Gianluca Boggio

Department of Neuroscience, Section of Psychiatry,, Università Cattolica del Sacro Cuore

Email: info@benthamscience.net

Giulia Mastroeni

Department of Neuroscience, Section of Psychiatry, Università Cattolica del Sacro Cuore

Email: info@benthamscience.net

Francesca Abate

Department of Neuroscience, Section of Psychiatry,, Università Cattolica del Sacro Cuore

Email: info@benthamscience.net

Eliana Conte

Department of Neuroscience, Section of Psychiatry, Università Cattolica del Sacro Cuore,

Email: info@benthamscience.net

Anna Quintano

Department of Neuroscience, Section of Psychiatry,, Università Cattolica del Sacro Cuore

Email: info@benthamscience.net

Lavinia De Chiara

, Struttura Residenziale Psichiatrica Samadi S.p.A.

Email: info@benthamscience.net

Laura Monti

UOS Clinical Psychology, Clinical Government, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Email: info@benthamscience.net

Giovanni Camardese

Department of Psychiatry,, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Email: info@benthamscience.net

Lucio Rinaldi

Department of Psychiatry,, Fondazione Policlinico Universitario Agostino Gemelli IRCCS,

Email: info@benthamscience.net

Alexia Koukopoulos

Azienda Ospedaliera Universitaria Policlinico Umberto I, Viale dell’Università 30

Email: info@benthamscience.net

Daniela Chieffo

UOS Clinical Psychology, Clinical Government, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Email: info@benthamscience.net

Gloria Angeletti

Sapienza University of Rome, Sant'Andrea Hospital, Sapienza University of Rome

Email: info@benthamscience.net

Marianna Mazza

Department of Psychiatry,, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Email: info@benthamscience.net

Bibliografia

  1. Davies, C.; Segre, G.; Estradé, A.; Radua, J.; De Micheli, A.; Provenzani, U.; Oliver, D.; Salazar de Pablo, G.; Ramella-Cravaro, V.; Besozzi, M.; Dazzan, P.; Miele, M.; Caputo, G.; Spallarossa, C.; Crossland, G.; Ilyas, A.; Spada, G.; Politi, P.; Murray, R.M.; McGuire, P.; Fusar-Poli, P. Prenatal and perinatal risk and protective factors for psychosis: A systematic review and meta-analysis. Lancet Psychiatry, 2020, 7(5), 399-410. doi: 10.1016/S2215-0366(20)30057-2 PMID: 32220288
  2. Howard, L.M.; Khalifeh, H. Perinatal mental health: A review of progress and challenges. World Psychiatry, 2020, 19(3), 313-327. doi: 10.1002/wps.20769 PMID: 32931106
  3. Orsolini, L.; Sceusa, F.; Pompili, S.; Mauro, A.; Salvi, V.; Volpe, U. Severe and persistent mental illness (SPMI) in pregnancy and breastfeeding: Focus on second-generation long acting injectable antipsychotics. Expert Opin. Drug Saf., 2021, 20(10), 1207-1224. doi: 10.1080/14740338.2021.1928634 PMID: 33966552
  4. Wesseloo, R.; Kamperman, A.M.; Bergink, V.; Pop, V.J.M. Thyroid peroxidase antibodies during early gestation and the subsequent risk of first-onset postpartum depression: A prospective cohort study. J. Affect. Disord., 2018, 225, 399-403. doi: 10.1016/j.jad.2017.08.058 PMID: 28850854
  5. Valdimarsdóttir, U.; Hultman, C.M.; Harlow, B.; Cnattingius, S.; Sparén, P. Psychotic illness in first-time mothers with no previous psychiatric hospitalizations: A population-based study. PLoS Med., 2009, 6(2), e1000013. doi: 10.1371/journal.pmed.1000013 PMID: 19209952
  6. O’Hara, M.W.; Wisner, K.L. Perinatal mental illness: Definition, description and aetiology. Best Pract. Res. Clin. Obstet. Gynaecol., 2014, 28(1), 3-12. doi: 10.1016/j.bpobgyn.2013.09.002 PMID: 24140480
  7. Cuomo, A.; Goracci, A.; Fagiolini, A. Aripiprazole use during pregnancy, peripartum and lactation. A systematic literature search and review to inform clinical practice. J. Affect. Disord., 2018, 228, 229-237. doi: 10.1016/j.jad.2017.12.021 PMID: 29275156
  8. Winans, E.A. Antipsychotics and Breastfeeding. J. Hum. Lact., 2001, 17(4), 344-347. doi: 10.1177/089033440101700408 PMID: 11847903
  9. Conejo-Galindo, J.; Sanz-Giancola, A.; Álvarez-Mon, M.Á.; Ortega, M.Á.; Gutiérrez-Rojas, L.; Lahera, G. Postpartum relapse in patients with bipolar disorder. J. Clin. Med., 2022, 11(14), 3979. doi: 10.3390/jcm11143979 PMID: 35887743
  10. Edinoff, A.N.; Sathivadivel, N.; McNeil, S.E.; Ly, A.I.; Kweon, J.; Kelkar, N.; Cornett, E.M.; Kaye, A.M.; Kaye, A.D. Antipsychotic use in pregnancy: Patient mental health challenges, teratogenicity, pregnancy complications, and postnatal risks. Neurol. Int., 2022, 14(1), 62-74. doi: 10.3390/neurolint14010005 PMID: 35076595
  11. Munk-Olsen, T.; Laursen, T.M.; Mendelson, T.; Pedersen, C.B.; Mors, O.; Mortensen, P.B. Risks and predictors of readmission for a mental disorder during the postpartum period. Arch. Gen. Psychiatry, 2009, 66(2), 189-195. doi: 10.1001/archgenpsychiatry.2008.528 PMID: 19188541
  12. Sprague, J.; Wisner, K.L.; Bogen, D.L. Pharmacotherapy for depression and bipolar disorder during lactation: A framework to aid decision making. Semin. Perinatol., 2020, 44(3), 151224. doi: 10.1016/j.semperi.2020.151224 PMID: 32199600
  13. McAllister-Williams, R.H.; Baldwin, D.S.; Cantwell, R.; Easter, A.; Gilvarry, E.; Glover, V.; Green, L.; Gregoire, A.; Howard, L.M.; Jones, I.; Khalifeh, H.; Lingford-Hughes, A.; McDonald, E.; Micali, N.; Pariante, C.M.; Peters, L.; Roberts, A.; Smith, N.C.; Taylor, D.; Wieck, A.; Yates, L.M.; Young, A.H. British association for psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J. Psychopharmacol., 2017, 31(5), 519-552. doi: 10.1177/0269881117699361 PMID: 28440103
  14. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; Chou, R.; Glanville, J.; Grimshaw, J.M.; Hróbjartsson, A.; Lalu, M.M.; Li, T.; Loder, E.W.; Mayo-Wilson, E.; McDonald, S.; McGuinness, L.A.; Stewart, L.A.; Thomas, J.; Tricco, A.C.; Welch, V.A.; Whiting, P.; Moher, D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 2021, 372(71), n71. doi: 10.1136/bmj.n71 PMID: 33782057
  15. ROBINS-E Development Group. Higgins, J.; Morgan, R.; Rooney, A.; Taylor, K.; Thayer, K.; Silva, R .; Lemeris, C.; Akl, A.; Arroyave, W.; Bateson, T.; Berkman, N.; Demers, P.; Forastiere, F.; Glenn, B.; Hróbjartsson, A.; Kirrane, E.; LaKind, J.; Luben, T.; Lunn, R.; McAleenan, A.; McGuinness, L.; Meerpohl, J.; Mehta, S.; Nachman, R.; Obbagy, J.; O'Connor, A.; Radke, E.; Savović, J.; Schubauer-Berigan, M.; Schwingl, P.; Schunemann, H.; Shea, B.; Steenland, K.; Stewart, T.; Straif, K.; Tilling, K.; Verbeek, V.; Vermeulen, R.; Viswanathan, M.; Zahm, S.; Sterne, J. Risk Of Bias In Non-randomized Studies of Exposure (ROBINS-E). Launch version, 20 June 2023. Available from: https://www.riskofbias.info/welcome/robins-e-tool (assessed on August 25, 2023.)
  16. Rieder, R.O.; Rosenthal, D.; Wender, P.; Blumenthal, H. The offspring of schizophrenics. Fetal and neonatal deaths. Arch. Gen. Psychiatry, 1975, 32(2), 200-211. doi: 10.1001/archpsyc.1975.01760200064006 PMID: 234727
  17. Milkovich, L.; van den Berg, B.J. An evaluation of the teratogenicity of certain antinauseant drugs. Am. J. Obstet. Gynecol., 1976, 125(2), 244-248. doi: 10.1016/0002-9378(76)90601-3 PMID: 773181
  18. McKeigue, P.M.; Lamm, S.H.; Linn, S.; Kutcher, J.S. Bendectin and birth defects: I. A meta‐analysis of the epidemiologic studies. Teratology, 1994, 50(1), 27-37. doi: 10.1002/tera.1420500105 PMID: 7974252
  19. Slone, D.; Siskind, V.; Heinonen, O.P.; Monson, R.R.; Kaufman, D.W.; Shapiro, S. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am. J. Obstet. Gynecol., 1977, 128(5), 486-488. doi: 10.1016/0002-9378(77)90029-1 PMID: 879206
  20. Godet, P.F.; Marie-Cardine, M. Neuroleptiques, schizophrénie et grossesse. Etude épidémiologique et tératologique. Encephale, 1991, 17(6), 543-547. PMID: 1687216
  21. Sharma, J.B.; Sharma, S. Role of thioridazine in unexplained infertility. Int. J. Gynaecol. Obstet., 1992, 37(1), 37-41. doi: 10.1016/0020-7292(92)90975-O PMID: 1346599
  22. Goldstein, D.J.; Corbin, L.A.; Fung, M.C. Olanzapine-exposed pregnancies and lactation: Early experience. J. Clin. Psychopharmacol., 2000, 20(4), 399-403. doi: 10.1097/00004714-200008000-00002 PMID: 10917399
  23. Diav-Citrin, O.; Shechtman, S.; Ornoy, S.; Arnon, J.; Schaefer, C.; Garbis, H.; Clementi, M.; Ornoy, A. Safety of haloperidol and penfluridol in pregnancy: A multicenter, prospective, controlled study. J. Clin. Psychiatry, 2005, 66(3), 317-322. doi: 10.4088/JCP.v66n0307 PMID: 15766297
  24. McKenna, K.; Koren, G.; Tetelbaum, M.; Wilton, L.; Shakir, S.; Diav-Citrin, O.; Levinson, A.; Zipursky, R.B.; Einarson, A. Pregnancy outcome of women using atypical antipsychotic drugs: A prospective comparative study. J. Clin. Psychiatry, 2005, 66(4), 444-449. doi: 10.4088/JCP.v66n0406 PMID: 15816786
  25. Reis, M.; Källén, B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J. Clin. Psychopharmacol., 2008, 28(3), 279-288. doi: 10.1097/JCP.0b013e318172b8d5 PMID: 18480684
  26. Babu, G.N.; Desai, G.; Tippeswamy, H.; Chandra, P.S. Birth weight and use of olanzapine in pregnancy: A prospective comparative study. J. Clin. Psychopharmacol., 2010, 30(3), 331-332. doi: 10.1097/JCP.0b013e3181db8734 PMID: 20473073
  27. Gilad, O.; Merlob, P.; Stahl, B.; Klinger, G. Outcome of infants exposed to olanzapine during breastfeeding. Breastfeed. Med., 2011, 6(2), 55-58. doi: 10.1089/bfm.2010.0027 PMID: 21034242
  28. Habermann, F.; Fritzsche, J.; Fuhlbrück, F.; Wacker, E.; Allignol, A.; Weber-Schoendorfer, C.; Meister, R.; Schaefer, C. Atypical antipsychotic drugs and pregnancy outcome: A prospective, cohort study. J. Clin. Psychopharmacol., 2013, 33(4), 453-462. doi: 10.1097/JCP.0b013e318295fe12 PMID: 23764684
  29. Sadowski, A.; Todorow, M.; Yazdani Brojeni, P.; Koren, G.; Nulman, I. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: A cohort study. BMJ Open, 2013, 3(7), e003062. doi: 10.1136/bmjopen-2013-003062 PMID: 23852139
  30. Bellet, F.; Beyens, M.N.; Bernard, N.; Beghin, D.; Elefant, E.; Vial, T. Exposure to aripiprazole during embryogenesis: A prospective multicenter cohort study. Pharmacoepidemiol. Drug Saf., 2015, 24(4), 368-380. doi: 10.1002/pds.3749 PMID: 25683615
  31. Cohen, L.S.; Viguera, A.C.; McInerney, K.A.; Freeman, M.P.; Sosinsky, A.Z.; Moustafa, D.; Marfurt, S.P.; Kwiatkowski, M.A.; Murphy, S.K.; Farrell, A.M.; Chitayat, D.; Hernández-Díaz, S. Reproductive safety of second-generation antipsychotics: Current data from the massachusetts general hospital national pregnancy registry for atypical antipsychotics. Am. J. Psychiatry, 2016, 173(3), 263-270. doi: 10.1176/appi.ajp.2015.15040506 PMID: 26441156
  32. Montastruc, F.; Salvo, F.; Arnaud, M.; Bégaud, B.; Pariente, A. Signal of gastrointestinal congenital malformations with antipsychotics after minimising competition bias: A disproportionality analysis using data from Vigibase. Drug Saf., 2016, 39(7), 689-696. doi: 10.1007/s40264-016-0413-1 PMID: 26961536
  33. Petersen, I.; McCrea, R.L.; Sammon, C.J.; Osborn, D.P.J.; Evans, S.J.; Cowen, P.J.; Freemantle, N.; Nazareth, I. Risks and benefits of psychotropic medication in pregnancy: Cohort studies based on UK electronic primary care health records. Health Technol. Assess., 2016, 20(23), 1-176. doi: 10.3310/hta20230 PMID: 27029490
  34. Petersen, I.; Sammon, C.J.; McCrea, R.L.; Osborn, D.P.J.; Evans, S.J.; Cowen, P.J.; Nazareth, I. Risks associated with antipsychotic treatment in pregnancy: Comparative cohort studies based on electronic health records. Schizophr. Res., 2016, 176(2-3), 349-356. doi: 10.1016/j.schres.2016.07.023 PMID: 27484686
  35. Huybrechts, K.F.; Hernández-Díaz, S.; Patorno, E.; Desai, R.J.; Mogun, H.; Dejene, S.Z.; Cohen, J.M.; Panchaud, A.; Cohen, L.; Bateman, B.T. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry, 2016, 73(9), 938-946. doi: 10.1001/jamapsychiatry.2016.1520 PMID: 27540849
  36. Hatters, F.S.; Moller-Olsen, C.; Prakash, C.; North, A. Atypical antipsychotic use and outcomes in an urban maternal mental health service. Int. J. Psychiatry Med., 2016, 51(6), 521-533. doi: 10.1177/0091217417696739 PMID: 28629296
  37. Shin, Y.J.; Choi, J.S.; Ahn, H.K.; Ryu, H.M.; Kim, M.Y.; Han, J.Y. Pregnancy outcomes in women reporting ingestion of levosulpiride in early pregnancy. J. Obstet. Gynaecol., 2017, 37(8), 992-995. doi: 10.1080/01443615.2017.1312307 PMID: 28631490
  38. Onken, M.; Mick, I.; Schaefer, C. Paliperidone and pregnancy: An evaluation of the German Embryotox database. Arch. Women Ment. Health, 2018, 21(6), 657-662. doi: 10.1007/s00737-018-0828-z PMID: 29569043
  39. Galbally, M.; Frayne, J.; Watson, S.J.; Snellen, M. Aripiprazole and pregnancy: A retrospective, multicentre study. J. Affect. Disord., 2018, 238, 593-596. doi: 10.1016/j.jad.2018.06.004 PMID: 29957476
  40. Cohen, L.S.; Góez-Mogollón, L.; Sosinsky, A.Z.; Savella, G.M.; Viguera, A.C.; Chitayat, D.; Hernández-Díaz, S.; Freeman, M.P. Risk of major malformations in infants following first-trimester exposure to quetiapine. Am. J. Psychiatry, 2018, 175(12), 1225-1231. doi: 10.1176/appi.ajp.2018.18010098 PMID: 30111186
  41. Anderson, K.N.; Ailes, E.C.; Lind, J.N.; Broussard, C.S.; Bitsko, R.H.; Friedman, J.M.; Bobo, W.V.; Reefhuis, J.; Tinker, S.C. Atypical antipsychotic use during pregnancy and birth defect risk: National Birth Defects Prevention Study, 1997–2011. Schizophr. Res., 2020, 215, 81-88. doi: 10.1016/j.schres.2019.11.019 PMID: 31761471
  42. Ellfolk, M.; Leinonen, M.K.; Gissler, M.; Lahesmaa-Korpinen, A.M.; Saastamoinen, L.; Nurminen, M.L.; Malm, H. Second-generation antipsychotics and pregnancy complications. Eur. J. Clin. Pharmacol., 2020, 76(1), 107-115. doi: 10.1007/s00228-019-02769-z PMID: 31680189
  43. Ellfolk, M.; Leinonen, M.K.; Gissler, M.; Kiuru-Kuhlefelt, S.; Saastamoinen, L.; Malm, H. Second-generation antipsychotic use during pregnancy and risk of congenital malformations. Eur. J. Clin. Pharmacol., 2021, 77(11), 1737-1745. doi: 10.1007/s00228-021-03169-y PMID: 34100993
  44. Freeman, M.P.; Viguera, A.C.; Góez-Mogollón, L.; Young, A.V.; Caplin, P.S.; McElheny, S.A.; Church, T.R.; Chitayat, D.; Hernández-Díaz, S.; Cohen, L.S. Reproductive safety of aripiprazole: Data from the massachusetts general hospital national pregnancy registry for atypical antipsychotics. Arch. Women Ment. Health, 2021, 24(4), 659-667. doi: 10.1007/s00737-021-01115-6 PMID: 33710399
  45. Viguera, A.C.; Freeman, M.P.; Góez-Mogollón, L.; Sosinsky, A.Z.; McElheny, S.A.; Church, T.R.; Young, A.V.; Caplin, P.S.; Chitayat, D.; Hernández-Díaz, S.; Cohen, L.S. Reproductive safety of second-generation antipsychotics: updated data from the massachusetts general hospital national pregnancy registry for atypical antipsychotics. J. Clin. Psychiatry, , 2021, 82(4), 20m13745. doi: 10.4088/JCP.20m13745
  46. Nguyen, T.; Frayne, J.; Watson, S.; Lebedevs, T.; Teoh, S.; Galbally, M. Long-acting injectable antipsychotic treatment during pregnancy: Outcomes for women at a tertiary maternity hospital. Psychiatry Res., 2022, 313, 114614. doi: 10.1016/j.psychres.2022.114614 PMID: 35576628
  47. Yakuwa, N.; Takahashi, K.; Anzai, T.; Ito, N.; Goto, M.; Koinuma, S.; Uno, C.; Suzuki, T.; Watanabe, O.; Yamatani, A.; Murashima, A. Pregnancy outcomes with exposure to second-generation antipsychotics during the first trimester. Clin. Psychiatry, 2022, 83(4), 21m14081. doi: 10.4088/JCP.21m14081
  48. Hálfdánarson, Ó.; Cohen, J.M.; Karlstad, Ø.; Cesta, C.E.; Bjørk, M.H.; Håberg, S.E.; Einarsdóttir, K.; Furu, K.; Gissler, M.; Hjellvik, V.; Kieler, H.; Leinonen, M.K.; Nørgaard, M.; Öztürk Esen, B.; Ulrichsen, S.P.; Reutfors, J.; Zoega, H. Antipsychotic use in pregnancy and risk of attention/deficit-hyperactivity disorder and autism spectrum disorder: A Nordic cohort study. Evid. Based Ment. Health, 2022, 25(2), 54-62. doi: 10.1136/ebmental-2021-300311 PMID: 34810174
  49. Straub, L.; Hernández-Díaz, S.; Bateman, B.T.; Wisner, K.L.; Gray, K.J.; Pennell, P.B.; Lester, B.; McDougle, C.J.; Suarez, E.A.; Zhu, Y.; Zakoul, H.; Mogun, H.; Huybrechts, K.F. Association of antipsychotic drug exposure in pregnancy with risk of neurodevelopmental disorders: A National Birth Cohort Study. JAMA Intern. Med., 2022, 182(5), 522-533. doi: 10.1001/jamainternmed.2022.0375 PMID: 35343998
  50. Huybrechts, K.F.; Straub, L.; Karlsson, P.; Pazzagli, L.; Furu, K.; Gissler, M.; Hernandez-Diaz, S.; Nørgaard, M.; Zoega, H.; Bateman, B.T.; Cesta, C.E.; Cohen, J.M.; Leinonen, M.K.; Reutfors, J.; Selmer, R.M.; Suarez, E.A.; Ulrichsen, S.P.; Kieler, H. Association of in utero antipsychotic medication exposure with risk of congenital malformations in Nordic countries and the US. JAMA Psychiatry, 2023, 80(2), 156-166. doi: 10.1001/jamapsychiatry.2022.4109 PMID: 36477338
  51. Cohen, L.S.; Church, T.R.; Freeman, M.P.; Gaccione, P.; Caplin, P.S.; Kobylski, L.A.; Arakelian, M.; Rossa, E.T.; Chitayat, D.; Hernández-Díaz, S.; Viguera, A.C. Reproductive safety of lurasidone and quetiapine: Update from the national pregnancy registry for psychiatric medications. J. Womens Health , 2023, 32(4), 452-462. doi: 10.1089/jwh.2022.0310 PMID: 36716275
  52. Viguera, A.C.; Freeman, M.P.; Kobylski, L.A.; Rossa, E.T.; Gaccione, P.; Chitayat, D.; Hernández-Díaz, S.; Cohen, L.S. Risk of major malformations following first-trimester exposure to olanzapine: Preliminary data from the Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications. J. Clin. Psychopharmacol., 2023, 43(2), 106-112. doi: 10.1097/JCP.0000000000001665 PMID: 36825887
  53. Liu, X.; Kolding, L.; Momen, N.; Gasse, C.; Pedersen, L.H. Maternal antipsychotic use during pregnancy and congenital malformations. Am. J. Obstet. Gynecol. MFM, 2023, 5(6), 100950. doi: 10.1016/j.ajogmf.2023.100950 PMID: 37015311
  54. Schrijver, L.; Robakis, T.K.; Kamperman, A.M.; Bijma, H.; Honig, A.; van Kamp, I.L.; Hoogendijk, W.J.G.; Bergink, V.; Poels, E.M.P. Neurodevelopment in school‐aged children after intrauterine exposure to antipsychotics. Acta Psychiatr. Scand., 2023, 147(1), 43-53. doi: 10.1111/acps.13517 PMID: 36333825
  55. Idänpään-Heikkilä, J.; Alhava, E.; Olkinuora, M.; Palva, I. Letter: Clozapine and agranulocytosis. Lancet, 1975, 306(7935), 611. doi: 10.1016/S0140-6736(75)90206-8 PMID: 51442
  56. Meltzer, H.Y.; Bastani, B.; Ramirez, L.; Matsubara, S. Clozapine: New research on efficacy and mechanism of action. Eur. Arch. Psychiatry Neurol. Sci., 1989, 238(5-6), 332-339. doi: 10.1007/BF00449814 PMID: 2569975
  57. Perrault, G.; Schoemaker, H.; Scatton, B. Place de l’amisulpride dans la classe des neuroleptiques atypiques. Encephale, 1996, 22(Spec No 2), 3-8. PMID: 8767034
  58. Citrome, L.; Holt, R.I.G.; Walker, D.J.; Hoffmann, V.P. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin. Drug Investig., 2011, 31(7), 455-482. doi: 10.2165/11589060-000000000-00000 PMID: 21495734
  59. Lambert, T.J.R. Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder. Evid. Based Ment. Health, 2009, 12(2), 50. doi: 10.1136/ebmh.12.2.50 PMID: 19395609
  60. Tyrrell, J.; Richmond, R.C.; Palmer, T.M.; Feenstra, B.; Rangarajan, J.; Metrustry, S.; Cavadino, A.; Paternoster, L.; Armstrong, L.L.; De Silva, N.M.G.; Wood, A.R.; Horikoshi, M.; Geller, F.; Myhre, R.; Bradfield, J.P.; Kreiner-Møller, E.; Huikari, V.; Painter, J.N.; Hottenga, J.J.; Allard, C.; Berry, D.J.; Bouchard, L.; Das, S.; Evans, D.M.; Hakonarson, H.; Hayes, M.G.; Heikkinen, J.; Hofman, A.; Knight, B.; Lind, P.A.; McCarthy, M.I.; McMahon, G.; Medland, S.E.; Melbye, M.; Morris, A.P.; Nodzenski, M.; Reichetzeder, C.; Ring, S.M.; Sebert, S.; Sengpiel, V.; Sørensen, T.I.A.; Willemsen, G.; de Geus, E.J.C.; Martin, N.G.; Spector, T.D.; Power, C.; Järvelin, M.R.; Bisgaard, H.; Grant, S.F.A.; Nohr, E.A.; Jaddoe, V.W.; Jacobsson, B.; Murray, J.C.; Hocher, B.; Hattersley, A.T.; Scholtens, D.M.; Davey Smith, G.; Hivert, M.F.; Felix, J.F.; Hyppönen, E.; Lowe, W.L., Jr; Frayling, T.M.; Lawlor, D.A.; Freathy, R.M. Genetic evidence for causal relationships between maternal obesity-related traits and birth weight. JAMA, 2016, 315(11), 1129-1140. doi: 10.1001/jama.2016.1975 PMID: 26978208
  61. Schmidt, M.; Schmidt, S.A.J.; Sandegaard, J.L.; Ehrenstein, V.; Pedersen, L.; Sørensen, H.T. The danish national patient registry: A review of content, data quality, and research potential. Clin. Epidemiol., 2015, 7, 449-490. doi: 10.2147/CLEP.S91125 PMID: 26604824
  62. Lynge, E.; Sandegaard, J.L.; Rebolj, M. The danish national patient register. Scand. J. Public Health,, 2011, 39(7_suppl)(Suppl.), 30-33. doi: 10.1177/1403494811401482 PMID: 21775347
  63. Cohen, L.S.; Viguera, A.C.; McInerney, K.A.; Kwiatkowski, M.A.; Murphy, S.K.; Lemon, E.L.; Hernández-Díaz, S. Establishment of the national pregnancy registry for atypical antipsychotics. J. Clin. Psychiatry, 2015, 76(7), 986-989. doi: 10.4088/JCP.14br09418 PMID: 25939066
  64. Vari, I.S.; Balkau, B.; Kettaneh, A.; André, P.; Tichet, J.; Fumeron, F.; Caces, E.; Marre, M.; Grandchamp, B.; Ducimetière, P. Ferritin and transferrin are associated with metabolic syndrome abnormalities and their change over time in a general population: Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care, 2007, 30(7), 1795-1801. doi: 10.2337/dc06-2312 PMID: 17416791
  65. Musenga, A.; Saracino, M.; Sani, G.; Raggi, M. Antipsychotic and antiepileptic drugs in bipolar disorder: The importance of therapeutic drug monitoring. Curr. Med. Chem., 2009, 16(12), 1463-1481. doi: 10.2174/092986709787909604 PMID: 19355900
  66. Wang, Z.; Brauer, R.; Man, K.K.C.; Alfageh, B.; Mongkhon, P.; Wong, I.C.K. Prenatal exposure to antipsychotic agents and the risk of congenital malformations in children: A systematic review and meta‐analysis. Br. J. Clin. Pharmacol., 2021, 87(11), 4101-4123. doi: 10.1111/bcp.14839 PMID: 33772841
  67. Hillemacher, T.; Simen, S.; Rehme, M.K.; Frieling, H. Antipsychotics during pregnancy: A systematic review. Nervenarzt, 2021, 92(5), 494-500. doi: 10.1007/s00115-020-01006-8
  68. Gentile, S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr. Bull., 2010, 36(3), 518-544. doi: 10.1093/schbul/sbn107 PMID: 18787227
  69. Gentile, S.; Fusco, M.L. Schizophrenia and motherhood. Psychiatry Clin. Neurosci., 2019, 73(7), 376-385. doi: 10.1111/pcn.12856 PMID: 31026107
  70. Oyebode, F.; Rastogi, A.; Berrisford, G.; Coccia, F. Psychotropics in pregnancy: Safety and other considerations. Pharmacol. Ther., 2012, 135(1), 71-77. doi: 10.1016/j.pharmthera.2012.03.008 PMID: 22483705
  71. Coughlin, C.G.; Blackwell, K.A.; Bartley, C.; Hay, M.; Yonkers, K.A.; Bloch, M.H. Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy. Obstet. Gynecol., 2015, 125(5), 1224-1235. doi: 10.1097/AOG.0000000000000759 PMID: 25932852
  72. Centorrino, F.; Fogarty, K.V.; Sani, G.; Salvatore, P.; Cincotta, S.L.; Hennen, J.; Guzzetta, F.; Talamo, A.; Saadeh, M.G.; Baldessarini, R.J. Use of combinations of antipsychotics: McLean Hospital inpatients, 2002. Hum. Psychopharmacol., 2005, 20(7), 485-492. doi: 10.1002/hup.719 PMID: 16116665
  73. Centorrino, F.; Fogarty, K.V.; Sani, G.; Salvatore, P.; Cimbolli, P.; Baldessarini, R.J. Antipsychotic drug use: McLean Hospital, 2002. Hum. Psychopharmacol., 2005, 20(5), 355-358. doi: 10.1002/hup.700 PMID: 15957153

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bentham Science Publishers, 2024